Theravance Biopharma
TBPH
118 hedge funds and large institutions have $549M invested in Theravance Biopharma in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 46 reducing their positions, and 13 closing their positions.
238,100% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $1K
25% more capital invested
Capital invested by funds: $439M → $549M (+$110M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
3% more funds holding
Funds holding: 115 → 118 (+3)
1.81% more ownership
Funds ownership: 96.22% → 98.02% (+1.8%)
28% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$1.63M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
+$1.61M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.17M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.14M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$620K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$10.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.52M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$2.61M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$2.51M |
| 5 |
Millennium Management
New York
|
-$1.08M |
TBPH Hedge Fund Activity: Q4 2023 in Review
118 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2023, worth a combined $549M — up 25% from $439M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TBPH positions and 13 closed out — a net gain of 3 holders — while 33 added to existing stakes and 46 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $1.63M. The largest seller was Park West Asset Management, cutting an estimated $10.9M.
- 118 institutional investors held Theravance Biopharma (TBPH) as of Q4 2023, up from 115 in Q3 2023.
- Funds reported $549M of Theravance Biopharma stock for Q4 2023, up 25% quarter-over-quarter.
- 16 funds opened new Theravance Biopharma positions in Q4 2023 and 13 closed out, a net change of +3 holders.
- The largest Theravance Biopharma buyer in Q4 2023 was D.E. Shaw & Co, an estimated $1.63M added.
- The largest Theravance Biopharma seller in Q4 2023 was Park West Asset Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2023.